BAY 3630942
Alternative Names: BAY-3630942Latest Information Update: 07 Jul 2025
At a glance
- Originator Bayer
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer; Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacokinetics data from a preclinical trial in Hepatocellular carcinoma presented at the 116th Annual Meeting of the American Association for Cancer Research(AACR-2025)
- 31 Mar 2025 Bayer completes a phase I trial in Solid tumours and Liver cancer in USA (IV) (NCT06345001)
- 28 Aug 2024 Phase-I clinical trials in Liver cancer in USA (IV) (NCT06345001)